Phase 2: testing candonilimab combined with fruquintinib and paclitaxel albumin-bound for Stomach Neoplasms
This is a Phase II Study of Candonilimab Combined with Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Official registry: https://clinicaltrials.gov/study/NCT07920224 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · enrollment listed as 59
What this phase means
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are candonilimab combined with fruquintinib and paclitaxel albumin-bound. The registry lists allocation as na. This is a Phase II Study of Candonilimab Combined with Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
They plan to enroll about 59 people at Wuhan. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Single-Arm, Multicenter, Phase II Study of Candonilimab Combined With Fruquintinib With or Without Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Therapy Containing a PD-(L)1 Inhibitor
Interventions: candonilimab combined with fruquintinib and paclitaxel albumin-bound
Primary outcome (registry wording): Objective Response Rate (ORR)
Who it is for (from inclusion criteria)
- Ages 18 Years to 75 Years
- Aged 18 to 75 years (inclusive);
- Pathologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma;
- Prior failure of first-line standard chemotherapy;
- HER2-negative status;
- how well you can do daily activities (ECOG score) of 0 to 2;
- Expected survival of ≥3 months;
- Presence of at least one measurable lesion, defined as:
Who the registry excludes
- Patients will be excluded from this study if they meet any of the following criteria:
- Inability to comply with the study protocol or study procedures;
- Prior treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors or prior use of immune checkpoint inhibitors;
- History of other malignant tumors within the past 5 years, except for basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix after curative resection;
- Presence of central nervous system (CNS) metastases or history of brain metastases prior to enrollment;
- Diagnosis of autoimmune disease or history of autoimmune disease within 4 weeks prior to enrollment;
- Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
Public study contact (from the registry)
Hongli Liu
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Union Hospital — Wuhan, Hubei, China (recruiting)
FAQ about this NCT record
Is NCT07920224 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07920224?
Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07920224?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary